Earnshaw S, Carlsen J, McDade C, Le Coent V, Sable B, Dassaud J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing given an updated reimbursement approach. Presented at the AABB Virtual 2021 Annual Meeting; October 17, 2021.
Earnshaw S, Beyhaghi H, McDade C, Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States. Transfusion. 2021 Oct;61(10):2885-97. doi: 10.1111/trf.16589
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9
Bryan A, Earnshaw SR, McDade C, Ines M, Micallef C, Enoch DA. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected Aspergillus infection. Poster presented at the 2021 Virtual 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); July 9, 2021.
Brodtkorb T-H, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the U.S. Poster presented at the 2021 Virtual AMCP; April 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).
Earnshaw S, McDade C, Marriott R, Daane L, Le Coent V, Yang J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing. Poster presented at the 2021 31st International Society of Blood Transfusion (ISBT) Virtual Conference; June 2, 2021. [abstract] Vox Sang. 2021; 116(Suppl 1):167.